Evidence map›Paper›PMID 26410353›Full record

ReviewBiological psychiatry2016

A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.

David Feifel, Paul D Shilling, Kai MacDonald

Open access · greenAbstract readReview
In one paragraph

Review in Biological psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Epigenetic Control in Schizophrenia.Sub-cellular biochemistry · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

David FeifelDepartment of Psychiatry, University of California, San Diego, La Jolla, California. Electronic address: dfeifel@ucsd.edu.
Paul D ShillingDepartment of Psychiatry, University of California, San Diego, La Jolla, California.
Kai MacDonaldDepartment of Psychiatry, University of California, San Diego, La Jolla, California.
University of California, San Diego · US

Funding

Oxytocin as a therapeutic target for SchizophreniaR01MH103421 · NIMH · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI FEIFEL, DAVID · 2015 to 2019
$1.8M
NIMH NIH HHS R01 MH103421NIMH NIH HHS R01 MH103421-01A1
6 · The paper itself

Abstract

Schizophrenia is a disabling, heterogeneous disorder with clinical features that can be parsed into three domains: positive symptoms, negative symptoms, and cognitive deficits. Current antipsychotic drugs produce fairly robust clinical benefit against positive symptoms but typically have minimal therapeutic effects on negative symptoms and cognitive deficits. Oxytocin (OT) is a nonapeptide that, in addition to its role as a hormone regulating peripheral reproductive-relevant functions, acts as a neurotransmitter in the brain. Several lines of preclinical and clinical research suggest that the OT system may play a role in regulating the expression of schizophrenia spectrum disorders and that targeting the central OT system may yield novel treatments to address these symptoms. In this review, we summarize the extant preclinical and clinical evidence relevant to the role of OT in schizophrenia with particular emphasis on its putative therapeutic effects on each of the three above-mentioned clinical domains.

Indexed as

Schizophrenic PsychologyAnimalsBrainCognitionCognition DisordersDisease Models, AnimalHumansOxytocinSchizophreniaOxytocinAntipsychoticCognitive deficitsNegative symptomsOxytocinPositive symptomsSchizophrenia

Identifiers

PMID26410353
PMCPMC5673255
OpenAlexW1441608289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.